Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,127,863
  • Shares Outstanding, K 29,189
  • Annual Sales, $ 332,070 K
  • Annual Income, $ 18,250 K
  • EBIT $ 2 M
  • EBITDA $ 11 M
  • 60-Month Beta 1.14
  • Price/Sales 3.48
  • Price/Cash Flow 40.27
  • Price/Book 2.48

Options Overview Details

View History
  • Implied Volatility 57.75% (+6.71%)
  • Historical Volatility 65.41%
  • IV Percentile 23%
  • IV Rank 27.24%
  • IV High 100.20% on 10/16/25
  • IV Low 41.85% on 01/22/25
  • Expected Move (DTE 12) 2.03 (5.26%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 32
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 1,156
  • Open Int (30-Day) 1,110
  • Expected Range 36.61 to 40.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year 0.32
  • Growth Rate Est. (year over year) -153.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.51 +18.86%
on 11/10/25
40.61 -4.85%
on 11/28/25
+5.07 (+15.10%)
since 11/05/25
3-Month
21.28 +81.58%
on 09/15/25
40.61 -4.85%
on 11/28/25
+15.08 (+64.01%)
since 09/05/25
52-Week
14.59 +164.84%
on 08/04/25
40.61 -4.85%
on 11/28/25
+6.48 (+20.15%)
since 12/05/24

Most Recent Stories

More News
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

FRIENDSWOOD, Texas, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has...

CSTL : 38.64 (-2.47%)
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

FRIENDSWOOD, Texas, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating...

CSTL : 38.64 (-2.47%)
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

FRIENDSWOOD, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive...

CSTL : 38.64 (-2.47%)
Castle Biosciences Reports Third Quarter 2025 Results

Delivered Q3 2025 revenue of $83 million Q 3 2025 non-dermatologic revenue increased by 67% over Q 3 2024 Q 3 2025 total test reports for our core revenue drivers (DecisionDx ®...

CSTL : 38.64 (-2.47%)
Castle Biosciences Launches AdvanceAD-Txâ„¢ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

FRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the launch...

CSTL : 38.64 (-2.47%)
Castle Biosciences to Participate in Upcoming Investor Conferences

FRIENDSWOOD, Texas, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive...

CSTL : 38.64 (-2.47%)
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

FRIENDSWOOD, Texas, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating...

CSTL : 38.64 (-2.47%)
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

FRIENDSWOOD, Texas, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating...

CSTL : 38.64 (-2.47%)
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

This new histological subtype data confirms DecisionDx-Melanoma’s clinical value across the spectrum of melanoma Castle Biosciences will also present validation data on its atopic dermatitis pipeline...

CSTL : 38.64 (-2.47%)
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will...

CSTL : 38.64 (-2.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 41.42
2nd Resistance Point 40.76
1st Resistance Point 39.70
Last Price 38.64
1st Support Level 37.98
2nd Support Level 37.32
3rd Support Level 36.26

See More

52-Week High 40.61
Last Price 38.64
Fibonacci 61.8% 30.67
Fibonacci 50% 27.60
Fibonacci 38.2% 24.53
52-Week Low 14.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar